Noah Capurso, MD

Clinical Update

Boost or Bust: Navigating the Risks of Prescription Stimulants

October 1, 2024

David Stiffler, MD. Clinical Associate Professor of Psychiatry and Medical Director of the Steven A. Cohen Military Family Center at NYU Grossman School of Medicine, New York, NY.

Noah Capurso, MD, MHS. Associate Professor of Psychiatry, Yale University, and Editor-in-Chief, The Carlat Addiction Treatment Report.

Drs. Stiffler and Capurso have no financial relationships with companies related to this material.

Prescription stimulants, while effective for treating ADHD, are widely taken without a prescription, particularly by young adults for cognitive enhancement, weight loss, and recreational purposes. This misuse poses serious risks, from developing stimulant use disorder to experiencing severe cardiovascular and psychiatric effects. In this article, you'll learn about the prevalence and patterns of stimulant misuse, its associated dangers, and tips on how to manage it in clinical practice.

Clinical Update

Overview of Stimulants

October 1, 2024

Michael Weaver, MD, FASAM and Noah Capurso, MD

Michael Weaver, MD, DFASAM. Professor and Medical Director, Center for Neurobehavioral Research on Addiction at the University of Texas Medical School, Houston, TX.

Noah Capurso, MD, MHS. Associate Professor of Psychiatry, Yale University, and Editor-in-Chief, The Carlat Addiction Treatment Report.

Drs. Weaver and Capurso have no financial relationships with companies related to this material.

This article offers an insightful overview of the pharmacology of various stimulant drugs, their potential for misuse, and the dangers they pose—especially with rising overdose rates due to contamination with fentanyl. Learn about the history, various classes of stimulants, and the treatments available for stimulant use disorder, as well as the crucial harm reduction strategies aimed at minimizing risks.

Clinical Update

A New Era for Buprenorphine

September 26, 2024

Noah Capurso, MD

Noah Capurso, MD, MHS.

Associate Professor of Psychiatry, Yale University, New Haven, CT; Editor-in-Chief, The Carlat Addiction Treatment Report.

Dr. Capurso has no financial relationships with companies related to this material.

A buprenorphine boot camp for all who need to know how to use it in the post-X-waiver age.

Clinical Update

Post X-Waiver Buprenorphine Prescribing

September 26, 2024

Noah Capurso, MD

Noah Capurso, MD, MHS. Associate Professor of Psychiatry, Yale University, New Haven, CT; Editor-in-Chief, The Carlat Addiction Treatment Report.

Dr. Capurso has no financial relationships with companies related to this material.

All clinicians need to know how to use buprenorphine under the DEAs new regulations. Meanwhile, the fentanyl crisis is changing how we use it. Noah Capurso shows us how to navigate these waters.

Clinical Update

A Clinician’s Guide to Drug Courts

July 1, 2024

Stephen Wemakor, MD and Noah Capurso, MD

Stephen Wemakor, MD, Department of Psychiatry, Yale University, New Haven, CT; Noah Capurso, MD, MHS, Assistant Professor of Psychiatry, Yale University, & Editor-in-Chief, The Carlat Addiction Treatment Report.

Drs. Wemakor and Capurso have no financial relationships with companies related to this material.

Many of your patients with substance use disorders will become involved with the legal system over the course of their work with you, and one of the most common avenues is through the drug
court system. Here, we provide the basics of how drug courts function and review how best to work with these courts when they request information.

Contingency Management with Dr. Dominick DePhilippis

June 3, 2024

Noah Capurso, MD and Dominick DePhilippis, PhD

In today's episode, Dr. DePhilippis tells us all about Contingency Management: what it is, how it works, and its evidence for the treatment of stimulant use disorders.

Stimulant Update with Dr. Brian Hurley

April 15, 2024

Noah Capurso, MD and Brian Hurley, MD, MBA, FAPA, DFASAM

In today's episode, Dr. Brian Hurley provides expert insights into the current state of stimulant use disorder, its implications across different regions, and available treatment options.

Clinical Update

Three Buprenorphine Dosing Strategies When Transitioning From Other Opioids

April 1, 2024

Monthe Kofos, DO and Noah Capurso, MD

Monthe Kofos, DO. Addiction Psychiatry Fellow, Yale University, New Haven, CT.

Noah Capurso, MD, MHS. Associate Professor of Psychiatry, Yale University, New Haven, CT; Editor-in-Chief, The Carlat Addiction Treatment Report.

Dr. Kofos and Dr. Capurso have no financial relationships with companies related to this material.

The process of starting a patient on buprenorphine, called an induction, can be a bit tricky and puts a patient at risk of a precipitated opioid withdrawal. In this article, we discuss the three most common buprenorphine induction approaches, review the pros and cons of each, and include straightforward guidance that will help you perform a successful buprenorphine induction for your patients.

Clinical Update

Treating Opioid Use Disorder During Pregnancy

April 1, 2024

Ariadna Forray, MD and Noah Capurso, MD

Ariadna Forray, MD. Associate Professor of Psychiatry; Chief of Psychological Medicine Section, Psychiatry; Director, Center for Wellbeing of Women and Mothers; Yale Medical Director, ACCESS Mental Health for Moms, New Haven, CT.

Noah Capurso, MD, MHS. Associate Professor of Psychiatry, Yale University, New Haven, CT; Editor-in-Chief, The Carlat Addiction Treatment Report.

Dr. Forray and Dr. Capurso have no financial relationships with companies related to this material.

As the overall prevalence of opioid use disorder has increased, so to has the prevalence of opioid use during pregnancy. Opioid use during pregnancy can put both your patient and the baby at risk, making proper treatment with MOUD essential. In this article, we outline the special considerations for the treatment of OUD during pregnancy and discuss how to prescribe MOUD safely.

Clinical Update

Xylazine: An Emerging Threat in the Opioid Overdose Epidemic

October 31, 2023

Roberto Sanchez, MD and Noah Capurso, MD

Roberto Sanchez, MD. Addiction psychiatry fellow, Yale University School of Medicine, New Haven, CT.

Noah Capurso, MD, MHS. Assistant professor of psychiatry, Yale University, New Haven, CT; Editor-in-Chief, The Carlat Addiction Treatment Report.

Dr. Sanchez and Dr. Capurso have no financial relationships with companies related to this material.

Xylazine is the latest contaminant being found in the American illicit drug supply. A non-opioid itself, xylazine is usually combined with fentanyl, with which it has synergistic sedative effects. Patients using xylazine can have profound levels of sedation and develop severe peripheral wounds. In this article, we discuss xylazine essentials and cover harm reduction strategies to help keep your patients safe.